Ceribell Inc. Chief Executive Officer Chao Xingjuan sold 6,068 ordinary shares on August 21, 2026, for a total of $145,753 at $24.02 per share, according to regulatory filings.
The disposal was executed to cover tax withholding obligations associated with the vesting of restricted stock units, the company disclosed. Xingjuan retains direct ownership of 781,731 Ceribell shares and acts as co-administrator of the ACP 2021 Trust, which holds an additional 369,088 shares. She disclaims beneficial ownership of the trust’s holdings beyond her pecuniary interest.
Ceribell’s shares have surged 109% over the past 52 weeks, reaching a high of $25.33, though the stock is currently assessed as overvalued by InvestingPro relative to its fair value estimate. The company’s gross profit margin stands at 88.9%, and its balance sheet shows a cash position exceeding total debt.
The transaction follows Ceribell’s second-quarter fiscal 2026 results, which reported revenue of $28.1 million, a 33% year-over-year increase. The company added 32 accounts during the quarter, slightly below Canaccord’s estimate of 36. Ceribell reported a loss of $0.51 per share, wider than the expected $0.36 loss.
Regulatory progress included FDA approval to expand the indicated use of its devices to pediatric and neonatal patients. The company is also advancing products for seizure detection, delirium monitoring, and pediatric care. Analysts at Canaccord raised their price target to $26 from $25 while maintaining a buy rating, while BTIG increased its target to $30 from $28, citing growth prospects and leadership in point-of-care rapid EEG technology.
